Key Facts · 2026-09-27
- Under EC 1223/2009, a distributor launching its own label becomes the brand owner and must appoint a Responsible Person, a recurring cost that did not exist while acting as a reseller.
- A Product Information File must be retained for 10 years after the last batch of a product is placed on the European market.
- Own-label production starts where white-label runs start: 300-2,000 units for stock formulas and 500-5,000 units for base-derived semi-custom work.
- Unsellable own-label stock is the hidden cost, because stock bought in a 1,000-2,000 unit run cannot be returned to the brand that originally supplied it.
- Channel conflict appears when the new own label sits in the same shop window as the third-party brands the distributor still has to sell for 2 more seasons.
- Own-label assortments across European drugstore and pharmacy chains have expanded through the 2020s, which is what keeps compressing third-party resale margins.
The Old Profit Structure Was Eroding From Four Directions
This distributor had built a competent agency business: it represented four European skincare brands in a mid-sized EU market, held the local inventory, and earned a margin on every carton sold into pharmacies and independent drugstores. That model was dependable for two decades.
Four things chipped at it. Marketplaces started discounting the same SKUs to European consumers directly. Online e-tail grew faster than the distributor's own counter sales. Retailers pushed for higher listing fees. And the brands themselves began splitting supply, giving the largest accounts a parallel import route that bypassed the local partner entirely.
We were not losing because our shelves were worse. We were losing because somebody else could sell the same bottle three clicks away.
Why Own Label Looked Like the Only Exit and What It Actually Fixed
Own label restored two things the agency model had taken away: full margin control and a reason for the retailer to keep the account. Exclusive product ranges also made the distributor harder to displace, because the retailer had invested window space in something only this partner could supply.
It did nothing for the underlying problem, though. The distributor still had to compete for the consumer's attention, and it now had to do that with a brand it had no consumer insight for.
The Three Costs Nobody Prices In
The financial model presented to the board showed goods and marketing. What it omitted was the compliance appointment, the inventory that could no longer be returned, and the internal friction of selling against your own range.
Each of these is manageable, but each is permanent. A distributor that treats them as one-off project costs will be re-litigating the decision in eighteen months.
Sequencing the Pivot Without Breaking the Agency Business
The decision that made this work was timing. Rather than launching against the existing portfolio, the distributor waited for a natural contract renewal, then negotiated own-label exclusivity into the new agreement with the two brands least affected by the conflict.
The internal sequence below ran over eleven months and kept the agency revenue intact through the entire build.
- Audit which agency brands had the most volatile pricing, since those were the lowest-risk first own-label targets.
- Appoint a Responsible Person and confirm who holds the compliance duty before a single sample is formulated.
- Start with white-label stock formulas at 300-2,000 units, which needs no new development cycle and ships in 2-4 weeks.
- Move to base-derived semi-custom for the second range at 500-5,000 units, where the formula can reflect local skin needs.
- Keep existing agency lines in the same store window for at least two seasons so shoppers read the own label as an addition.
What Changed in the European Pharmacy Channel
In Germany and Austria, pharmacy counters have become a legitimate route for own-label skincare, but only where the packaging can withstand close questioning. Customers read INCI lists, so an own-label product claiming active content has to be able to name the concentration and the evidence.
That requirement pulled the distributor toward slightly higher MOQs. Semi-custom runs at 500-5,000 units cost more per unit than stock formulas, but they are the only version that can carry a defensible claim in a European pharmacy conversation.
The lesson for other distributors is that the pivot is not a marketing project. It is a compliance project with a packaging brief attached.
- Compliance is permanent: a Responsible Person appointment and a 10-year Product Information File retention duty.
- Inventory risk is asymmetric: unsold own-label stock cannot be returned to the supplier who made it.
- Channel conflict is real, and the only mitigation is timing, not discounting.
The pivot is not a marketing project. It is a compliance project with a packaging brief attached.
Frequently Asked Questions
Model your own-label margin properly
Tell us your market, channel and target categories. We will return per-SKU minimums, a Responsible Person cost range and the lead time you should plan against.
Start your match